PYPD News and Press, PolyPid Ltd. From 12/22/20

Single Local Treatment of OncoPLEX Showed Improved Overall Survival and Significantly Less Tumor Recurrence, and Reduced Systemic Toxicity Compared to Multiple Injections with Standard Systemic Chemotherapy in a Syngeneic Mouse Model for Solid Tumors of Colon Carcinoma Compa...

In another active week for the IPO market, eight companies completed offerings, with the largest and most anticipated IPO, ContextLogic, putting on an underwhelming performance. Surprisingly, this came alongside the best performing IPO of 2020 as Wunong Net Technology traded up over 1...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadIt is a very light calendar ahead of the Christmas break with just a few earnings reports and no investor conferences at ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

PolyPid ([[PYPD]] -5.5%) has enrolled and randomized the first patient in the company's second Phase 3 trial, SHIELD II, evaluating its lead product candidate, D-PLEX100, for the prevention of post-abdominal surgery incisional infection (soft tissue).Enrollment in first Phase 3 clinical trial...

Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021 PETAH TIKVA, Israel, Dec. 16, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on dev...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

PETAH TIKVA, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announc...

The FDA grants Breakthrough Therapy Designation to PolyPid's (PYPD) lead product candidate D-PLEX100 for the prevention of post-abdominal surgery incisional infection (soft tissue).Breakthrough Therapy status provides for more intensive guidance from the FDA on development...